News | Left Atrial Appendage (LAA) Occluders | July 01, 2015

SentreHEART Receives FDA Approval for AMAZE Trial of Lariat Suture Delivery Device

Trial will evaluate ligation of left atrial appendage as adjunctive treatment for atrial fibrillation

SentreHeart, Lariat Suture Delivery Device, FDA, AMAZE Trial, AFib, LAA

July 1, 2015 - SentreHeart Inc. announced that it has received approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in a clinical study of the Lariat Suture Delivery Device. The randomized, controlled clinical study, known as the AMAZE Trial, will evaluate the use of the Lariat device for the ligation, or closure, of the left atrial appendage (LAA) as an adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation (AFib).

"The LAA is an important site for atrial fibrillation initiation and persistence, and its exclusion using the Lariat device as an adjunct to conventional ablation could be a major breakthrough in decreasing recurrence in patients with persistent atrial fibrillation," said Dhanunjaya Lakkireddy, M.D., FACC, FHRS, professor of medicine, director, Center for Excellence in AF and Complex Arrhythmias, University of Kansas Medical Center. "The AMAZE trial is rigorously designed and we believe will further validate the mechanical and electrical isolation benefits of the Lariat device, which has the potential to become a standard of care in treating persistent or longstanding persistent atrial fibrillation."

Recent studies have demonstrated that the device not only closes the LAA mechanically but can also isolate electrical activity within the LAA, a known trigger for AFib. The objective of the AMAZE Trial is to demonstrate that the Lariat for LAA closure, plus a pulmonary vein isolation (PVI) ablation, will lead to a reduced incidence of recurrent AFib compared to PVI alone, with a high safety profile.

The study is comprised of two stages. The overall study plan is to enroll a maximum of 600 persistent or longstanding persistent AFib patients who are candidates for PVI catheter ablation at up to 50 centers. The first stage of the AMAZE Trial will enroll up to 175 patients at 15 centers.

"The left atrial appendage has been accurately termed our most lethal human attachment," stated James L. Cox, M.D., the surgeon who developed the gold-standard Cox-maze procedure as a cure for AFib. "The Lariat is the only percutaneous device that can provide the electromechanical isolation of the myocardium of the LAA by devascularization and, when combined with PVI ablation, would seem to be the one most likely to improve catheter ablation outcomes for AFib."

PVI catheter ablation is the standard of care interventional treatment for patients with persistent and longstanding persistent AFib; however, not all electrical activity originates from the pulmonary veins. The LAA has been known to play a role in triggering recurrence of AFib after treatment with PVI catheter ablation, and is the source of most stroke-causing blood clots (thrombus) in AFib patients.

The Lariat Suture Delivery Device is indicated for suture placement and knot tying in surgical procedures where soft tissues are being approximated and/or ligated with a pre-tied polyester suture. SentreHEART received FDA 510(k) clearances for the Lariat in 2006, 2009 and 2014. The device also has CE Mark approval in Europe.

For more information: www.sentreheart.com

Related Content

Videos | Left Atrial Appendage (LAA) Occluders| November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders| March 29, 2017
March 29, 2017 — For patients with...
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
SentreHeart, Eclipse Surgical Device, left atrial appendage, LAA closure, first clinical use, Poland
News | Left Atrial Appendage (LAA) Occluders| October 13, 2016
SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical Device, which is...
St. Jude Medical, Amplatzer Amulet LAA occluder, left atrial appendage, IDE trial
News | Left Atrial Appendage (LAA) Occluders| September 02, 2016
St. Jude Medical Inc. announced the start of the St. Jude Medical Amplatzer Amulet IDE trial of the company’s Amplatzer...
Overlay Init